Founded in 2010, ICE Bioscience has been committed to delivering excellent services in early drug discovery, especially in Immuno-Oncology, Cardiovascular, and CNS diseases areas. ICE Bioscience has fully established service departments of Biology, Electrophysiology, Biochemistry, ADME/DMPK, in vivo pharmacology, and R&D Center to develop innovative assays and platforms. We have 75,000+ sqft of lab space, and 300+ dedicated and experienced drug discovery professionals. We have wide target-based panel screening platforms that are ready to use, expanding diverse techniques related to Biology and Pharmacology, to support various drug discovery purposes for different indications and clinical needs.

Currently, ICE Bioscience provides fully validated assay solutions for 100+ ion channels,1000+ Kinases/enzymes,150+ GPCRs,40+ nuclear receptors assays, and epigenetics and DDR targets, all of which cover most of the druggable targets. We already established platforms for protein production, Biochemistry, Immunology, Oncology, Electrophysiology, in vitro Cardiac and CNS Pharmacology, off-target safety evaluation, Cardiac safety evaluation, DMPK, etc. We make the DMTA cycle (Design-Make-Test-Analysis cycle) run efficiently and risk-free for our client’s innovative drug discovery pipelines.

ICE Bioscience provides cost-effective, customized, fast-TAT, and flexible FTE (and hybrid) working models. Currently, we are providing services to over 700 biotech and pharmaceutical companies global wide. Our expertise and experience in preclinical biology service provides not only high-quality results but also help our clients to manage and reduce potential risks of their early drug discovery pipelines and programs. Our vision is to fully support our clients to transform the horizon of their therapeutic areas.

Key features of ICE Bioscience’s drug discovery service:

• Whether you’re delving into biochemical pathways or exploring cellular functionalities, our target-based assays deliver robust data, empowering researchers to make informed decisions in drug discovery and development.

• Whether you’re assessing compound stability, metabolism, or bioavailability, our DMPK capabilities empower you with the knowledge needed for optimizing lead compounds and advancing them toward successful clinical outcomes.

• Unique and specialty assays and platforms. We proudly offer: SafetyOne-44, and SafetyMax-90 panels for off-target safety screening and to reduce risks in the later stage of drug discovery pipelines; ICE Bioscience also offers 416 kinase panel, which is the largest kinase panel using activity assay formats.

• Our translational biology expertise encompasses a spectrum of translational studies, including biomarker identification, target validation, and mechanism-of-action investigations. By seamlessly integrating molecular and cellular findings, we facilitate the transition of promising candidates from the laboratory to clinical settings.

• Scientific and regulatory expertise: staff at ICE Bioscience has a staff of Ph.D. and medical professionals (>30%) highly experienced in drug discovery and have innovative mindsets to help clients to develop unique assays and solutions for novel target screening.

With 13+ years of service legacy in early drug discovery, ICE Bioscience’s mission is to expedite and reduce the risk of our client’s drug discovery pipelines and contribute to the improvement of global healthcare with our advanced technologies and dedicated science team.